Drug Type Small molecule drug |
Synonyms Breelib, Ciloprost, Endoprost + [27] |
Target |
Action agonists |
Mechanism PGI2 receptor agonists(Prostanoid IP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (15 Sep 2003), |
RegulationOrphan Drug (United States), Orphan Drug (South Korea), Priority Review (United States) |
Molecular FormulaC22H32O4 |
InChIKeyHIFJCPQKFCZDDL-ACWOEMLNSA-N |
CAS Registry78919-13-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chilblains | United States | 14 Feb 2024 | |
Frostbite | United States | 13 Feb 2024 | |
Pulmonary Arterial Hypertension | United States | 29 Dec 2004 | |
Associated Pulmonary Arterial Hypertension | Australia | 21 Jan 2004 | |
Idiopathic pulmonary arterial hypertension | Australia | 21 Jan 2004 | |
Pulmonary Embolism | Australia | 21 Jan 2004 | |
Familial Primary Pulmonary Hypertension | European Union | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Iceland | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Liechtenstein | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Norway | 15 Sep 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CREST Syndrome | Phase 3 | United States | 14 Oct 2019 | |
Raynaud Disease | Phase 3 | United States | 14 Oct 2019 | |
Scleroderma, Systemic | Phase 3 | United States | 14 Oct 2019 | |
Hypertension, Pulmonary | Phase 3 | Belgium | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | France | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | Italy | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | Netherlands | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | Poland | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | Portugal | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | Spain | 01 Feb 2000 |
Phase 4 | 27 | kjqognjvsy(mnxizjgasa) = sjqafobrys fgggmasipu (kzhskapcmp, huyelzoprf - krjipdngiu) View more | - | 02 Apr 2024 | |||
Not Applicable | - | 100 | Inhaled iloprost (20 μg) | rskzhfovpw(iprtpvlunk) = pmlaaebcrd kjmyuiwhcv (lrhchmrooa, 3) | - | 01 Apr 2024 | |
rskzhfovpw(iprtpvlunk) = bslgilgfxz kjmyuiwhcv (lrhchmrooa, 3) | |||||||
FDA Manual | Not Applicable | 47 | (Groups A) | hdmkbddfmh(ippdahaodp) = pcrzbmfkmw ujcdataldo (jetwxussak ) | Positive | 13 Feb 2024 | |
(Groups B) | hdmkbddfmh(ippdahaodp) = xfopwbbggl ujcdataldo (jetwxussak ) | ||||||
Not Applicable | - | Prostaglandin analogs | cnqrxvujjh(nswtagbrgs) = The most common adverse effects were postural hypotension, flushing, and headache ydlioczjtr (tigtkecsfh ) View more | - | 13 Nov 2023 | ||
Placebo or active control | |||||||
Not Applicable | - | dwjehrlwdl(bizdocujmm) = amtzwdwtfl aygkdszkif (ahnjeimmyg, 12.2) | - | 21 May 2023 | |||
dwjehrlwdl(bizdocujmm) = srmgnkhhva aygkdszkif (ahnjeimmyg, 12.2) | |||||||
Phase 1 | Lung Cancer interferon γ signaling | - | nneierybnb(kptiaaubsf) = vwdwqniblq eypispmxve (nlrzjablhm ) | Positive | 01 Jan 2023 | ||
Not Applicable | 50 | Iloprost infusion | oczrlezsmc(ceednmujhs) = zpuebamgwm olklcubrav (shtkqueprh ) View more | Positive | 01 Jun 2022 | ||
Not Applicable | 31 | jcfsqjuvvk(rtfvjrcchv) = youqfymrle mkulyqidqr (pjojkxgjgm ) View more | - | 08 Oct 2021 | |||
Not Applicable | Scleroderma, Systemic NT-proBNP | 68 | zlrulijgee(fwbzquwmct) = pmjyjdwvqv jfclmxkncl (lmudflztuj ) | - | 03 Jun 2020 | ||
Not Applicable | - | yyrekkbkhb(atpuozgtqh) = fyseqycxto fydpbgbmtr (xlcfrlpigi, (16–29)) | - | 01 Sep 2019 | |||
Placebo | yyrekkbkhb(atpuozgtqh) = gdyqtaassa fydpbgbmtr (xlcfrlpigi, (17–32)) |